

RESEARCH

Open Access

Human immune responses to *Plasmodium falciparum* infection: molecular evidence for a suboptimal TH α β and TH17 bias over ideal and effective traditional TH1 immune response

Wan-Chung Hu^{1,2}

Abstract

Background: Using microarray analysis, this study showed up-regulation of toll-like receptors 1, 2, 4, 7, 8, NF- κ B, TNF, p38-MAPK, and MHC molecules in human peripheral blood mononuclear cells following infection with *Plasmodium falciparum*.

Methods: This analysis reports herein further studies based on time-course microarray analysis with focus on malaria-induced host immune response.

Results: The results show that in early malaria, selected immune response-related genes were up-regulated including α β and γ interferon-related genes, as well as genes of IL-15, CD36, chemokines (CXCL10, CCL2, S100A8/9, CXCL9, and CXCL11), TRAIL and IgG Fc receptors. During acute febrile malaria, up-regulated genes included α β and γ interferon-related genes, IL-8, IL-1b IL-10 downstream genes, TGFB1, oncostatin-M, chemokines, IgG Fc receptors, ADCC signalling, complement-related genes, granzymes, NK cell killer/inhibitory receptors and Fas antigen. During recovery, genes for NK receptors and granzymes/perforin were up-regulated. When viewed in terms of immune response type, malaria infection appeared to induce a mixed TH1 response, in which α and β interferon-driven responses appear to predominate over the more classic IL-12 driven pathway. In addition, TH17 pathway also appears to play a significant role in the immune response to *P. falciparum*. Gene markers of TH17 (neutrophil-related genes, TGFB1 and IL-6 family (oncostatin-M)) and TH α β (IFN- γ and NK cytotoxicity and ADCC gene) immune response were up-regulated. Initiation of TH α β immune response was associated with an IFN- α β response, which ultimately resulted in moderate-mild IFN- γ achieved via a pathway different from the more classic IL-12 TH1 pattern.

Conclusions: Based on these observations, this study speculates that in *P. falciparum* infection, TH α β /TH17 immune response may predominate over ideal TH1 response.

Keywords: TH1, TH2, TH17, TH α β , Malaria, Immune response

Background

TH1 has been suggested to be the dominant and protective immune response against malaria both in rodents and humans [1,2]. Yet the blood stage of *Plasmodium falciparum* can serve to immunosuppress the host's immune response to the liver stage of the parasite [3]

Dendritic cell maturation is inhibited by *P. falciparum*-infected red blood cells (RBCs) [4]; monocyte maturation is also suppressed by malaria pigments (haemozoin), and low serum IL-12 was reported in severe malaria [5,6]. These observations suggest that the IL-12-driven TH1, IFN γ -dominant response patterns seen following *P. falciparum* infection may not be functioning optimally; thus, against this background data, one may ask how the infected host is capable of mounting an effective TH1 response against the blood-borne stage of this parasite? An

Correspondence: lukluk73_2006@yahoo.com.tw

¹Department of International Health, Johns Hopkins University School of Public Health, Baltimore, MD 21205, USA

²Department of Neurology, Shin Kong Memorial Hospital, No.95, Wen Chang Road, Shih Lin District, Taipei, Taiwan

alternative pathway may be needed to achieve this host immune response.

To gain a better understanding of host immune response patterns associated with *P. falciparum* infection in humans, this study carried out transcriptional profiling using microarray analysis of peripheral blood mononuclear cells (PBMCs) after *P. falciparum* infection. The earlier analysis showed an up-regulation of gene expression for toll-like receptor signalling, NF- κ B, TNF, IFN- γ , IL-1 β , p38 MAPK, MHC class I and II molecules [7]. This study further analysed the data focusing on the specific type or types of host immune response induced by infection. Results indicated an up-regulation of TGF- β and the IL-6 family gene (oncostatin M), both of which induce TH17 immune response. This study also observed an elevation in the expression of interferon gamma, NK cell cytotoxicity, antibody-dependent cell cytotoxicity (ADCC), which are triggered by interferon alpha/beta (TH α β), instead of IL-12 (TH1). These results suggest multiple immune pathways may be activated following infection with *P. falciparum*. For the purpose of this study have classified these additional pathways as: TH α β and TH17 immune response. The TH α β pathway is not generally recognized within the immunology community as a distinct T cell maturation pathway while the TH17 response pattern has only recently been recognized [8]. However, TH α β responses in which α and β interferons drive a succession of cellular process leading to mid-moderate IFN- γ production and NK cell and ADCC activation have been described in the host response to viruses but they have not been shown to play an important role in the maturation of the anti-malaria adaptive immune response.

To further clarify this point, traditionally TH1 leads to immune response against intracellular bacteria and protozoa, and TH α β against viral infections. Macrophage activation is characteristic of traditional TH1 immune response, while NK activation (natural cytotoxicity and ADCC) is more characteristic of TH α β immune response. In addition, TH17 immune response is typical immunological pathway against extracellular bacteria and fungi. Pathogens may induce ineffective host immune response for immune evasion. Thus, malaria infection appears to be somewhat unique in that it appears to elicit a combined response reflective of both TH17 and TH α β host immune response alternative to effective TH1 immune response.

Methods

Ethical statement

This study was approved by Johns Hopkins University School of Public Health Institutional Research Board and Cameroon Department of Health Institutional Research Board. Written informed consent was obtained from each individual of this study.

Previous analysis

Subject recruitment, sample collection and preparation, and RNA [ribonucleic acid] purification were described previously in Ockenhouse et al. [7]. Briefly, two groups of subjects were recruited for this study after Johns Hopkins University Institutional Review Board and US Army HSRRB ethical approvals were obtained. In the study cohort, 22 subjects, 20–45 years of age, were recruited from the Walter Reed Army Institute of Research (WRAIR). Subjects agreed to receive mosquito bites from laboratory-reared *Anopheles stephensi* infected by *P. falciparum* (3D7 strain). Once parasitaemia was detected in the subjects' peripheral blood, the subjects received treatment with chloroquine. Blood samples were drawn during the un-infected baseline period (U) and again, when parasitaemia was found for the first time (early malaria (E)).

In the other study cohort, 15 adults were recruited from Cameroon. These subjects were 19–49 years of age with acute *P. falciparum* infection. All suffered from typical relapsing fever and blood smears showed parasitaemia. Patients were excluded if they actively suffered from other infectious or inflammation diseases. These subjects received at least one week of anti-malarial drug treatment (Cotecxin). Blood drawing was performed during the acute febrile infection period (A) and one month later during the recovery period (R). During the recovery period, physical examinations and blood smears were performed to ensure that malaria symptoms were no longer present and parasitaemia was no longer detectable.

In the first study cohort, PBMCs were separated from whole blood samples by Ficoll-gradient at WRAIR. In the second study cohort, blood was collected in CPT [Cell Preparation Tube] tubes and PBMCs were isolated after centrifuge. A RNA stabilizing reagent-RNA later (Ambion, CA, USA) was added and samples were shipped to the USA on dry ice. Total RNA was extracted from both sets of samples using Trizol. The quality of sample RNA was estimated by spectrometry (OD > 1.8) and gel electrophoresis.

Microarray preparation

Affymetrix U133A GeneChips (Affymetrix, Santa Clara, CA, USA) were used in this study. The GeneChips contain 22,283 probe-sets, including 14,500 known well-characterized human genes and 18,400 transcripts. Before chip hybridization, a QIAGEN RNeasy clean-up kit was used to purify total RNA. Processing of templates for analysis on the Affymetrix U133A GeneChip was performed in accordance with methods described in the Affymetrix Technical Manual, Revision Three. Total RNA from the blood samples were hybridized into the arrays. Detailed cDNA preparation, *in vitro* transcription, staining, and scanning of Affymetrix U133A

GeneChips were described previously in Ockenhouse et al. [7] paper.

Data analysis

This study used GeneSpring software and GeneSpring default normalization to perform one-way ANOVA tests, using un-infected samples as baseline. Significantly up-regulated genes were selected if false discovery rate (FDR) was < 0.05 and fold change was $> 1.5 \times$ when compared to un-infected baseline. These genes were placed into three groups based on expression levels in different stages of the infection. In addition, Pearson's correlation analysis and Rank correlation analysis were performed to find the relationship between expression levels of genes after malaria infection. Pathway analysis was performed by using the Pathway Architect (Stratagene Inc, CA, USA) software to identify the specific immunological pathways involved.

Microarray validation

In order to validate the study's microarray results, several assays were used including flow cytometry and commercial kits for plasma protein expression. Peripheral blood mononuclear cells analysis was done by a FACS-can flow cytometer (Becton-Dickinson, Mountain View, CA) using a panel of mouse anti-human monoclonal antibodies such as ICAM1 antibody before and after malaria challenge. Measuring the chemokine levels including CXCL10, CXCL9, and CCL2 in paired plasma samples collected before and after malaria challenge were done by using commercial kits (R&D systems, Minneapolis, MN). These validation assays were described in the previous Ockenhouse et al. [7] paper.

Microarray accession numbers

The Affymetrix data sets can be accessed at Gene Expression Omnibus [www.ncbi.nlm.nih.gov/geo/] under the accession number GSE5418.

Results

A total of 2,894 genes were differentially expressed out of the 22,283 probe sets in Affymetrix U133A GeneChip based on the criteria of data analysis. Gene expression patterns were measured in individuals with pre-symptomatic, experimental, early malarial infection and in subjects with naturally acquired acute febrile malarial infection. A baseline set of data derived from 22 uninfected healthy US subjects was used for gene comparison in samples from early malarial infection, acute febrile malarial infection and recovery stage. This baseline dataset is considered appropriate for comparisons between Cameroonian samples and USA samples because of the difficulty in collecting baseline samples from Cameroonian subjects that have had no prior exposure to malaria. As indicated previously,

the study site in Cameroon is endemic for malaria so it is difficult to find adults in the area that may not already be in the prodromal phase of malaria. The correlation of the average gene expression of baseline samples to the average gene expression from 22 USA subjects and from 15 Cameroonian adults exceeded 97%, indicating comparability of gene expression between datasets collected and processed at the WRAIR for US volunteers and at the Johns Hopkins Bloomberg School of Public Health for Cameroonian subjects.

TH1 immune response-related gene up-regulation during malaria

After *P. falciparum* infection, many immune response-related genes of the TH1 immunological pathway were up-regulated (Table 1). Although interferon alpha/beta was not detected in this study, the major transcription factor of interferon alpha/beta synthesis, IRF7, was up-regulated after malaria. Many interferon alpha/beta inducible genes were up-regulated during the early stage of malaria including: tryptophanyl-tRNA (IFI53), interferon alpha inducible protein 27 (IFI27), interferon-induced protein 44 (IFI44), interferon-stimulated protein 15KD (G1P2), interferon regulatory factor 1 (IRF1), 2'-5'-oligoadenylate synthetase 3 (OAS3), signal transducer and activator of transcription 1 (STAT1), interferon stimulated protein 35 (IFI35), Myxovirus resistance 1 (MX1), interferon-induced protein with tetratricopeptide repeat 4 (IFIT4), interferon-induced protein with tetratricopeptide repeat 1 (IFIT1), and interferon-induced protein with tetratricopeptide repeat 2 (IFIT2). The expression levels of the above genes were greater than two-fold in early malaria, as compared to un-infection baseline. In acute febrile malaria, the expression levels of most of the alpha/beta interferon genes tended to decline and all returned to baseline levels of expression during the recovery period (Table 1). Summary of all four immunological pathways in malarial infection is shown in Figure 1.

Interferon gamma and many interferon gamma-related genes were also up-regulated after malaria. These observations are consistent with a model in which malaria infection induces primarily a TH1 type immune response. These up-regulated genes included: interferon gamma, interferon inducible guanylate binding protein 1 (GBP1), interferon inducible guanylate binding protein 2 (GBP2), Janus kinase1 (JAK1), and transporter with antigen processing 1 (TAP1). The expression levels of GBP1, GBP2, and TAP1 ranged from 10.6- to 2.8-fold above baseline during early stage of malaria, and the expression level of GBP2 was greater than two-fold change during acute febrile malaria. These interferon gamma inducible genes all returned to baseline levels of expression during the recovery periods of the disease. The up-regulation of a

Table 1 TH1 (primarily THαβ) immune response related gene up-regulation after malaria

U	E	E/U	A	A/U	R	R/U	Gene	TH1 Immune response
0.595	3.656	6.144	1.213	2.038	1.003	<i>1.685</i>	IFI53	IFNα/b
0.898	3.089	3.439	1.298	1.445	1.132	1.260	IFI27	
0.825	2.375	2.878	1.077	1.305	0.928	1.124	IFI44	
0.552	2.093	3.791	1.158	2.097	0.933	<i>1.690</i>	G1P2	
0.51	2.07	4.058	1.031	2.021	0.947	<i>1.856</i>	IRF1	
0.813	1.763	2.168	1.08	1.328	0.926	1.138	OAS3	
0.579	1.829	3.158	1.058	<i>1.827</i>	0.977	<i>1.687</i>	STAT1	
0.722	1.773	2.455	1.091	<i>1.511</i>	0.952	1.318	IFI35	
0.881	1.586	<i>1.800</i>	1.069	1.213	0.898	1.019	OASL	
0.672	1.498	2.229	1.046	<i>1.556</i>	0.954	1.419	MX1	
0.662	1.532	2.314	1.26	<i>1.903</i>	1.097	<i>1.657</i>	IRF7	
0.898	4.549	5.065	0.992	1.104	0.894	0.995	IFIT4	
0.902	2.352	2.607	0.938	1.039	0.924	1.024	IFIT1	
0.931	1.935	2.078	1.065	1.143	0.964	1.035	IFIT2	
0.629	1.214	<i>1.930</i>	1.149	<i>1.826</i>	1.019	<i>1.620</i>	IFITM1	
0.655	1.043	<i>1.592</i>	2.424	3.700	1.694	2.586	IFNG	IFNγ
0.587	6.22	10.596	1.099	<i>1.872</i>	0.823	1.402	GBP1	
0.527	1.908	3.620	1.111	2.108	0.947	<i>1.796</i>	GBP2	
0.755	1.273	<i>1.686</i>	1.182	<i>1.565</i>	0.951	1.259	IFNGR2	
0.658	1.31	<i>1.990</i>	1.284	<i>1.951</i>	0.916	1.392	IFI30	
0.781	1.333	<i>1.706</i>	1.322	<i>1.692</i>	1.123	1.437	JAK2	
0.72	2.049	2.845	0.991	1.376	0.95	1.319	TAP1	
0.781	1.371	<i>1.755</i>	1.057	1.353	1.067	1.366	JAK1	
0.838	1.261	<i>1.504</i>	1.106	1.319	0.9	1.073	FcGR2B	
0.863	1.199	1.389	1.925	2.230	1.075	1.245	FcAR	
0.514	0.911	<i>1.772</i>	1.658	3.225	1.339	2.605	FcGR3B	ADCC
0.708	1.208	<i>1.706</i>	1.132	<i>1.598</i>	0.896	1.265	FcGR2A	
0.64	4.954	7.740	1.265	<i>1.976</i>	0.849	1.326	FcGR1A	
0.751	1.285	<i>1.711</i>	1.412	<i>1.880</i>	1.035	1.378	C1QA	
0.765	1.601	2.092	1.073	1.402	0.946	1.236	FcGR3A	
0.597	1.237	2.072	1.658	2.777	1.339	2.242	FcER1G	
0.953	0.658	0.690	1.298	1.362	1.502	<i>1.576</i>	CD3z	
0.819	0.676	0.825	1.455	<i>1.776</i>	1.329	<i>1.622</i>	Fyn	
0.656	1.029	<i>1.568</i>	1.219	<i>1.858</i>	1.035	<i>1.577</i>	DAP12	
0.848	0.985	1.161	1.271	<i>1.498</i>	1.204	1.419	Syk	
0.566	0.449	0.793	2.044	3.611	1.829	3.231	PI3K	
0.748	1.108	1.481	1.152	<i>1.540</i>	1.03	1.377	Rac1	
0.83	1.21	1.457	1.25	<i>1.506</i>	1.13	1.361	PAK1	
0.823	0.807	0.980	1.464	<i>1.778</i>	1.191	1.447	MAP2K1	
0.721	0.872	1.209	1.516	2.102	1.375	<i>1.907</i>	MAP2K2	
0.644	0.81	1.257	1.547	2.402	1.382	2.145	Arf6	
0.881	0.642	0.728	2.723	3.090	2.931	3.326	KLRC3	NK cell
0.829	0.868	1.047	1.26	<i>1.519</i>	1.492	<i>1.799</i>	NKEFB	

Table 1 TH1 (primarily THαβ) immune response related gene up-regulation after malaria (Continued)


0.927	0.848	0.914	1.442	<i>1.555</i>	1.432	<i>1.544</i>	KIR2DL3	
0.857	0.694	0.809	2.199	2.565	2.1	2.450	KIR3DL2	
0.77	3.235	4.201	0.835	1.084	0.798	1.036	TNFSF10	
0.653	1.242	<i>1.901</i>	1.152	<i>1.764</i>	1	<i>1.531</i>	Fas	
0.693	0.991	1.430	1.144	<i>1.650</i>	1.084	<i>1.564</i>	MICB	
0.901	0.772	0.856	1.439	<i>1.597</i>	1.31	1.453	ETS1	
0.704	0.899	1.276	1.596	2.267	1.379	<i>1.958</i>	CEBPg	
0.757	1.145	<i>1.512</i>	1.119	1.478	1.02	1.347	MEF	
0.638	0.765	1.199	1.674	2.623	1.458	2.285	ID2	
0.71	1.397	<i>1.967</i>	1.092	<i>1.538</i>	0.884	1.245	IL15	
0.908	0.738	0.812	1.521	<i>1.675</i>	1.626	<i>1.790</i>	GZMM	
0.768	0.962	1.252	1.568	2.041	1.199	<i>1.561</i>	CD58	
0.548	1.223	2.231	1.491	2.720	0.963	<i>1.757</i>	CCR1	TH1 Chemokine
0.381	0.974	2.556	2.085	5.472	1.713	4.496	CCL3	
0.689	0.735	1.066	3.206	4.653	2.65	3.846	CCL4	
0.986	5.194	5.267	1.045	1.059	0.956	0.969	CXCL10	
1.029	1.576	<i>1.531</i>	0.835	0.811	0.83	0.806	CXCL9	
0.824	1.265	<i>1.535</i>	0.924	1.121	0.808	0.980	CXCL11	
0.863	0.641	0.742	1.495	<i>1.732</i>	1.557	<i>1.804</i>	GZMK	CD8 T cell
0.795	0.651	0.818	1.98	2.490	1.739	2.187	GZMB	
0.881	0.638	0.724	1.236	1.402	1.522	<i>1.727</i>	GZMA	
0.829	0.765	0.922	1.432	<i>1.727</i>	1.385	<i>1.670</i>	RUNX3	
0.656	1.07	<i>1.631</i>	1.308	<i>1.993</i>	1.106	<i>1.685</i>	Rel	
0.925	0.812	0.877	1.497	<i>1.618</i>	1.593	<i>1.722</i>	CD3g	
0.871	0.892	1.024	2.021	2.320	1.719	<i>1.973</i>	CDC42	
0.749	0.692	0.923	1.885	2.516	1.524	2.034	Kras	
0.78	1.159	1.485	1.209	<i>1.55</i>	1.094	1.402	ICOS	
0.784	0.915	1.167	1.497	<i>1.909</i>	1.486	<i>1.895</i>	CD28	
0.77	1.007	1.307	1.224	<i>1.589</i>	1.038	1.348	Bcl10	
0.816	0.87	1.066	1.557	<i>1.908</i>	1.45	<i>1.776</i>	MALT1	

Bold means greater than 2-fold change.
 Italic means 1.5-2-fold change.
 Plane means no change.

number of TH1 chemokines over the malaria disease course was also consistent with a TH1 model of anti-malaria immune response. Up-regulated TH1 related chemokine genes included: CXCL10, CCL3, CCL3 and CCR1. The expression levels of CXCL10 (5.3-fold) was highest during the early phase of malaria, while CCR3 and CCL4 were higher during febrile and recovery stages of the disease (Table 1).

There were many ADCC and NK cell-related genes up-regulated after malaria. ADCC-related genes included: Fc receptors (Fc alpha receptor, Fc gamma receptor 3B, Fc gamma receptor 1A, and Fc gamma receptor 3A), and ADCC signalling genes (CD3z, Fyn, DAP12, Syk, PI3K, Rac1, PAK1, MAP2K1, MAP2K2, and Arf6).

NK cell-related genes included NK cell receptor-related genes (KLRC3 and KIR3DL2), TNF superfamily ligand 10 (TRAIL), NK cell-related transcription factors (CEBP-gamma), interleukin 15, and NK cell-restricted granzyme M. Interleukin 15 can enhance NK cell differentiation and proliferation. ADCC is mainly mediated by NK cells, but it can also be mediated by macrophages. Fc receptor and ADCC signalling gene up-regulation is consistent with the ADCC machinery being turned on after *P. falciparum* infection. Among the above genes, gene expression levels were greater than two-fold change (range two- to seven-fold; see Table 1) in early malaria including: Fc gamma receptor 1A, Fc gamma receptor 3A, Fc epsilon receptor 1G, and TRAIL. Gene expression levels were greater than



two-fold change in acute febrile malaria including: Fc alpha receptor, Fc gamma receptor 3B, Fc epsilon receptor 1G, PI3K, MAP2K2, Arf6, KLRC3, KIR3DL2, and CEBP gamma (range two- to four-fold). Gene expression levels were greater than two-fold change in the recovery period, including: Fc gamma receptor 3B, Fc epsilon receptor 1G, PI3K, Arf6, KLRC3, and KIR3DL2 range two- to three-fold). Although ADCC signalling genes were not greater than two-fold, they were higher than 1.5-fold change after malarial infection. CTL-related genes (CD8 T cells in Table 1) were only moderately up-regulated during malaria. Among these genes, granzyme B, CDC42, and Kras exhibited \geq two-fold change during acute febrile malaria. Granzyme B and Kras were \geq two-fold change in the recovery period.

Although macrophage/monocyte activation is traditionally considered to be a strong marker for classic TH1 type immune response, this study surprisingly

found that express levels of most macrophage activation genes were relatively unchanged or slightly suppressed after *P. falciparum* infection (Table 2). These data support the hypothesis that there may be two pathways involved in the induction of TH1 types of immune responses: a TH α β interferon driven path and IL-12 driven path (see Discussion). Most macrophage activation and proliferation-related genes were unchanged (Table 2). IL-12 is clearly the major cytokine needed to initiate a strong classic TH1 type immune response, and IL-12 expression levels remain unchanged over the course of this study (Table 2). This observation suggests that the induction of a TH1-type anti-malarial immune response may be driven by cytokines other than IL-12. Like IL-12, other traditional TH1 cytokine: IL-3, M-CSF, and GM-CSF can also cause macrophage proliferation but these genes are also not up-regulated in response to infection with *P. falciparum* (Table 2). In contrast, many macrophage

Table 2 TH1 (primary TH12) immune response unchanged after malaria

0.755	1.273	<i>1.686</i>	1.182	<i>1.565</i>	0.951	1.259	IFNGR2	Macrophage
1.02	0.91	0.892	1.16	1.137	1.13	1.107	CD40L	Activation
0.804	1.271	<i>1.580</i>	1.132	1.407	1.098	1.365	TNFalpha	
0.97	1.04	1.072	1.01	1.041	1.03	1.061	TNFbeta	
0.733	1.263	<i>1.723</i>	1.293	<i>1.763</i>	0.864	1.178	TLR2	
0.744	1.125	<i>1.512</i>	1.385	<i>1.861</i>	0.991	1.331	TLR4	
0.739	1.051	1.422	1.408	<i>1.905</i>	1.044	1.412	TLR8	
0.99	1.04	1.050	1.03	1.040	1	1.010	IL12A	
1.02	1.04	1.019	0.96	0.941	0.95	0.931	IL12B	
1.13	1.08	0.955	0.96	0.849	0.94	0.831	IL12RB1	
1.04	1.16	1.115	1.02	0.980	0.97	0.932	IL12RB2	
1.04	0.78	0.75	1.22	1.173	1.27	1.221	STAT4	
1.03	1.08	1.048	1.02	0.990	1.01	0.980	iNOS	
1.054	1	0.948	1	0.948	1.04	0.986	ASS	
1	1.27	1.27	0.94	0.94	0.96	0.96	MMP9	
0.87	0.98	1.126	1.19	1.367	1.12	1.287	TRAF6	
0.98	1.03	1.051	0.99	1.010	1	1.020	TRANCE	
1.05	1.06	1.009	0.94	0.895	0.94	0.895	RANK	
0.99	1.039	1.049	0.97	0.979	0.99	1	ERM	
1.07	1.08	1.009	0.93	0.869	0.92	0.859	M-CSF	Macrophage
1.02	1.03	1.009	0.97	0.950	0.97	0.950	GM-CSF	Proliferation
1.11	1.03	0.927	0.94	0.846	0.89	0.801	IL-3	
0.92	1.04	1.130	1.13	1.228	1.04	1.130	RUNX1	
0.86	0.89	1.034	0.85	0.988	0.84	0.976	Myb	
1.21	1.25	1.033	0.81	0.669	0.87	0.719	Myc	
1	1.24	1.24	1	1	0.95	0.95	CEBPalpha	
1.04	1.04	1	1	0.961	1.03	0.990	HOXB7	
1.06	1.17	1.103	0.95	0.896	0.97	0.915	GATA1	
1.07	1.06	0.990	0.95	0.887	0.98	0.915	GATA2	
1.12	1.19	1.062	0.82	0.732	0.86	0.767	Tal1	
0.358	0.952	2.659	2.495	6.969	1.351	3.773	MafB	
0.841	0.809	0.961	1.401	<i>1.665</i>	1.295	<i>1.539</i>	TGFBR2	Macrophage
0.85	1.355	<i>1.594</i>	1.024	1.204	0.727	0.855	CD36	Inhibition
0.706	0.972	1.376	1.307	<i>1.851</i>	1.209	<i>1.712</i>	CD47	
0.943	0.783	0.830	1.521	<i>1.612</i>	1.097	1.163	CD163	
0.522	0.781	1.496	1.776	3.402	1.556	2.980	JunB	
0.51	2.07	4.058	1.031	2.021	0.947	<i>1.856</i>	IRF1	
0.73	0.95	1.301	2.62	3.589	1.81	2.479	HMOX1	
0.83	1.24	1.493	1.27	<i>1.530</i>	0.97	1.168	SIRPalpha	
0.7	1.319	<i>1.884</i>	1.48	2.114	1.02	1.457	PU.1	

Bold means greater than 2-fold change.

Italic means 1.5-2-fold change.

Plane means no change.

inhibition-related genes were up-regulated after malaria, including haem oxygenase 1 (HMOX1), JunB, and IRF1. JunB, PU.1 and IRF1 suppress macrophage proliferation. As

indicated above, a macrophage differentiation inducer, MafB, is up-regulated after malaria. Its antagonists, JunB and PU.1, were also up-regulated, so the effect of MafB

could be suppressed. PU.1 up-regulation can drive monocytes to differentiate into dendritic cells instead of macrophages. Although macrophages can also express Fc receptor genes, this study thinks these Fc receptor expression after malaria should mainly occur in NK cells. The Fc receptor signalling pathway (ADCC signalling pathway) in NK cell was all up-regulated (Table 1). Also, DAP12 up-regulation can suppress Fc receptor signalling in macrophages, so it is less likely that these up-regulated Fc receptors belong to macrophages. Although IL-10 itself was not up-regulated, many IL-10 downstream genes were up-regulated as shown in Figure 1 of the previous analysis results [7]. IL-10 can activate NK cells and de-activate

macrophages. HMOX1 is the major downstream effector molecule to mediate IL-10 inhibition of macrophages. HMOX1 was up-regulated after malaria. HMOX1 generates CO molecule to mediate anti-inflammatory effects in macrophages, which is opposite to nitric oxide synthetase (iNOS), which generates NO molecule to cause inflammatory effects. Argininesuccinate synthetase (ASS) is the rate-limiting enzyme to synthesize arginine, the substrate of iNOS. iNOS is the central mediator representing macrophage classical activation, and unchanged ASS and iNOS express levels support the notion that macrophages are not being activated after malaria infection. In the study, macrophages were inhibited rather than activated after malaria.

Table 3 TH17 related gene up-regulation after malaria

U	E	E/U	A	A/U	R	R/U	Gene	TH17Immune response
0.767	0.775	1.010	1.275	1.662	1.382	1.801	IL32	IL17 CD4 Tcell
0.343	0.779	2.271	2.922	8.518	1.389	4.049	IL8	
0.805	1.265	1.571	2.276	2.827	1.931	2.398	IL1B	
0.804	1.271	1.580	1.132	1.407	1.098	1.365	TNFalpha	
0.653	1.019	1.560	1.346	2.061	1.156	1.770	TGFB1	
0.841	0.809	0.961	1.401	1.665	1.295	1.539	TGFBR2	
0.795	0.907	1.140	1.849	2.325	1.491	1.875	OSM	
0.77	1.333	1.731	1.04	1.350	0.865	1.123	STAT3	
0.764	0.894	1.170	2.98	3.900	1.648	2.157	CEBPD	
0.459	0.991	2.159	1.694	3.690	1.163	2.533	CEBPB	
0.903	1.552	1.718	0.899	0.995	0.787	0.871	S100A8	Neutrophil
0.707	1.568	2.217	1.049	1.483	0.852	1.205	S100A9	
0.667	0.97	1.454	2.827	4.238	1.699	2.547	CXCL2	
0.923	1.027	1.112	2.027	2.196	1.333	1.444	CXCL3	
0.745	1.4	1.879	1.182	1.586	0.946	1.269	CD63	
0.708	1.26	1.779	1.183	1.670	0.917	1.295	CD157	
0.722	1.948	2.698	1.155	1.599	0.923	1.278	ICAM1	
0.725	0.911	1.256	1.167	1.609	1.054	1.453	ITGB2	
0.954	2.945	3.087	0.939	0.984	0.801	0.839	NCF1	
0.827	1.471	1.778	1.116	1.349	0.953	1.152	NCF4	
0.742	1.047	1.411	1.202	1.619	1.011	1.362	CD97	
0.709	1.382	1.949	1.16	1.636	0.801	1.129	FPR1	
0.918	1.131	1.232	1.619	1.763	1.23	1.339	Pentraxin3	
0.723	1.08	1.493	2.135	2.952	1.895	2.621	PGES2	
0.635	1.087	1.711	2.079	3.274	1.218	1.918	C3AR1	Complement
0.623	0.908	1.457	2.628	4.218	1.571	2.521	C5R1	
0.552	0.881	1.596	2.297	4.161	1.392	2.521	DAF	
0.751	1.285	1.711	1.412	1.880	1.035	1.378	C1QA	
0.67	0.914	1.364	1.349	2.013	1.166	1.740	FactorD	
0.761	1.093	1.436	1.418	1.863	1.121	1.473	Properdin	

Bold means greater than 2-fold change.
 Italic means 1.5-2-fold change.
 Plane means no change.

Table 4 TH2 related gene unchanged after malaria

U	E	E/U	A	A/U	R	R/U	Gene	TH2Immune response
1.09	1.06	0.972	0.97	0.889	1.02	0.935	IL4	IL4 CD4 Tcell
1.07	1.08	1.009	0.97	0.906	1	0.934	IL4R	
1.02	1.08	1.058	0.99	0.970	0.97	0.950	IL5	
1.06	1	0.943	0.98	0.924	0.99	0.933	IL5R	
1.08	1.1	1.018	0.95	0.879	0.92	0.851	IL9	
1.08	1.08	1	0.99	0.916	0.95	0.879	IL9R	
0.94	0.99	1.053	1.15	1.223	1.09	1.159	IL10	
0.93	0.85	0.913	1.08	1.161	1.17	1.258	IL10RA	
1.09	1.05	0.963	0.95	0.871	0.92	0.844	IL13	
0.98	1.14	1.163	1.23	1.255	0.99	1.010	IL13RA1	
1.13	1.01	0.893	1.01	0.893	1.01	0.893	IL13RA2	
1.1	1.13	1.027	0.91	0.827	0.96	0.872	CCR3	
1.08	0.96	0.888	0.98	0.907	1.01	0.935	CCR4	
1.11	1.2	1.081	0.86	0.774	0.95	0.855	CCR8	
1.08	1.12	1.037	0.89	0.824	0.94	0.870	CCL17	
0.99	1.1	1.111	0.91	0.919	0.95	0.959	CCL22	
1.09	1.04	0.954	0.92	0.844	0.93	0.853	CRTH2	
1.05	0.94	0.895	1.08	1.028	0.98	0.933	CD30	
0.92	0.98	1.065	1.13	1.228	1.17	1.271	OX40	
1.32	1.31	0.992	0.93	0.704	0.89	0.674	OX40L	
1.01	0.88	0.871	1.01	1	0.99	0.980	STAT6	
1	0.92	0.92	1.18	1.18	1.16	1.16	GATA3	
0.98	1	1.020	0.96	0.979	1	1.020	NFATc	
0.92	0.91	0.989	1.27	1.380	1.31	1.423	Gfi-1	
0.96	1.09	1.135	1.1	1.145	1.07	1.114	SPHK1	
1.05	1.02	0.971	0.97	0.923	1	0.952	SH2D1A	
1.12	1.08	0.964	0.87	0.776	0.85	0.758	ST2L	
1.11	1.06	0.954	0.94	0.846	0.98	0.882	A3AR	Mast cell
1.1	1.13	1.027	0.91	0.827	0.96	0.872	CCR3	
1.03	1.22	1.184	0.89	0.864	0.99	0.961	FCER2	
1.14	0.63	<u>0.552</u>	1.17	1.026	1.72	1.508	FCER1A	
1.09	1.13	1.036	0.93	0.853	1.01	0.926	LTC4S	
0.95	0.96	1.010	1.11	1.168	1.05	1.105	MGST2	
0.89	0.93	1.044	1.19	1.337	1.13	1.269	MGST3	
0.92	0.92	1	0.84	0.913	0.85	0.923	CysLTR1	
1.07	1.04	0.971	0.94	0.878	0.94	0.878	CysLTR2	
1.02	1.08	1.058	0.99	0.970	0.97	0.950	IL5	Eosinophil
1.11	1.01	0.909	0.97	0.873	1.02	0.918	Eotaxin1	
1.18	1.17	0.991	0.88	0.745	0.89	0.754	Eotaxin2	

Italic means 1.5-2-fold change.

Plane means no change.

Underline means down-regulation.

In summary, many elements of TH1 immune response were up-regulated following infection with *P. falciparum*, including: interferon alpha/beta inducible genes, interferon

gamma inducible genes, NK cell-related genes (NK cell cytotoxicity), ADCC-related genes, TH1 chemokines, and CD8 T cell-related genes. However, macrophages appear to

become de-activated and do not appear to proliferate after malarial infection.

TH17 immune response related gene up-regulation during malaria

A number of genes associated with the newly described TH17 immune response pathway were up-regulated after infection with *P. falciparum* (Table 3). Of these genes, IL-8 showed the greatest degree of up-regulation over the entire course of the disease cycle (early, febrile period and recovery periods), with expression levels peaking during the febrile period of illness (8.5-fold increase; Table 3). Other up-regulated genes included other TH17-related cytokines, IL1 β , TGF β 1, and oncostatin M as well as TH17-related transcription factors, CEBP delta, and CEBP gamma. In addition, selected neutrophil-related genes were also up-regulated, including: neutrophil attracting chemokines, S100A9, CXCL2, and CXCL3, the neutrophil-related CD molecules, ICAM1, the NADPH oxidases gene NCF1, and acute reaction protein, PGE synthetase2. Many complement-related genes were also up-regulated including C3A receptor1, C5 receptor1, delay-accelerating factor (DAF), and Factor D.

TH2 immune response related genes unchanged during malaria

Most TH2 immune response-related genes were remarkably unchanged over the course of the malaria disease cycle (Table 4). An extensive analysis of TH2 cytokines and chemokines, as well as Mast cell and eosinophil genes revealed that gene expression level were essentially unaffected by infection with *P. falciparum*, thus providing strong evidence that TH2-type immune response was not significantly initiated during malaria in this study. Expression levels for only a single gene involved in Mast cell activation, Fc epsilon receptor 1A surface receptor, was modified during the malaria disease cycle. This gene was down-regulated during early malaria and mildly up-regulated during recovery period.

Gene-to-gene relationship

This study performed Pearson's correlation to analyse gene-to-gene relationship after malaria infection and found a number of relationships in the study subjects that were consistent with observations by other investigators in previous studies. This study observed a strong negative Pearson's correlation between the expression levels of STAT1 and STAT4 in early malaria infection and acute febrile malaria (Figure 2). There are positive Pearson's correlations between the expression level of STAT1 and Fc receptors (ADCC-related genes), but negative correlations between STAT4 and Fc receptors. These observations suggested STAT1 up-regulated Fc




Figure 2 Gene-to-gene correlation. This figure is to compare STAT1 and STAT4 gene correlation in acute stage of malarial infection. These twelve samples are from patients are Cameroon acute malaria patients. There is negative correlation between STAT1 and STAT4, Pearson's correlation coefficient (r) and its P value (p) were calculated for the graph.

receptors. There is negative correlation between STAT1 and STAT4. Although some previous studies found that STAT4, IL-12R, and Fc receptors are co-expressed, STAT4 is not correlated or even negatively correlated with these up-regulated Fc receptors in malarial infection. Fc receptors suppressed STAT4 expression or STAT4 suppressed Fc receptors (Table 5). Rank correlation has also been done, but there were no significant results. Rank correlation is stricter than Pearson's correlation. If the data are normally distributed, Pearson's correlation analysis is more suitable than Rank correlation analysis.

Immunological pathways


Pathway analysis was conducted to explore immunological genetic circuitry during malaria infection. This study selected IL-4, IL-12, TGF β 1/IL-6, IL-17, IFN- α / β as the central gene markers to explore possible networking among the 2,894 genes under analysis in this study. This study was able to identify only a few up-regulated


Table 5 Correlation between Fc receptor/complement receptor and STAT1/STAT4 in acute febrile malaria

Gene	STAT1	STAT4
FCER1G	0.9 (0.001)	-0.71 (0.01)
FCGR1A	0.88 (0.001)	-0.74 (0.01)
FCGR2A	0.79 (0.01)	-0.79 (0.01)
FCGR2B	0.74 (0.01)	-0.77 (0.01)
Fas	0.71 (0.01)	-0.64 (0.05)
C3AR	0.86 (0.001)	-0.73 (0.01)
DAF	0.64 (0.05)	-0.66 (0.02)
C1QA	0.71 (0.01)	-0.64 (0.05)
Properdin	0.82 (0.01)	-0.68 (0.02)

genes in this cluster that centred on IL-4 (Figure 3) or IL-12 (Figure 4). In contrast, gene networks centred on TGFB1/IL6, IL-17 (Figure 5), or IFN- α (Figure 3) were more dramatically altered during the malaria disease cycle. These results further support a model for malaria immune response in which IL-17/IFN-alpha/beta plays a more central regulatory role than IL-4 and IL-12. Figure 6 shows a sketch of the major pathways of host

immune response that are felt to play a role in recovery from malaria based on the observations made in this study, as well as those made by other investigators in previous research. The changes in their expression levels during the early, acute and recovery stages of *P. falciparum* infection are summarized in Figure 1. As shown in Figures 1, 7, 8 and 9, the expression of genes related to TH2 immune response were unchanged following





malaria infection, with most changes occurring in genes related to the TH17 and TH α β driven pathway of anti-malaria immune response.

Validation by plasma and PBMC protein expression

In the previous analysis, this study found out the concordance between transcription of genes and translation of proteins in malarial infection. This study demonstrated the similar up-regulation of ICAM1 level after malarial infection between microarray RNA result and surface protein expression detected by flow cytometry. CXCL10, CXCL9, and CCL2 chemokine expressions are up-regulated in this microarray finding. The above chemokine proteins are also identified in plasma samples after malarial infection. These results show that this microarray analysis is validated as shown in Figure 4 in [7].

Discussion

Host immune response can be categorized into TH1, TH2, and TH17 immune response pathways. TH1 immune responses (Type 1 immune response) are IFN- γ and IgG-mediated and they play an important role in host responses to viruses and intracellular bacteria/

protozoa. TH2 immune responses are IL-4 and IgE-mediated immune response are important to host responses to helminths; TH17, initiated by TGF- β , IL-6 and IL-17 are important in host responses to extracellular bacterial pathogens [9-11]. In this research, these data suggest that there should be a new immunological pathway derived from the original TH1 immune response: TH α β . TH α β is named after IFN α / β . In this model, TH α β is triggered by interferon alpha/beta + IL-10 and TH1 is triggered by interleukin 12. Based on previous work by others, TH α β is important in host immune response against virus infection; TH1 is important in host immune response against intracellular bacteria/protozoa. Different types of host immune response have different effector cells. In TH2 immune response, the effector cells are mast cells, eosinophils, basophils, IgE/IgG4 secreting B cells, and IL-4 secreting CD4 T cells. In TH17 immune response, the effector cells are neutrophils, IgA/IgM/IgG2 secreting B cells, and IL-17 secreting CD4 T cells. In TH α β immune response, the effector cells are NK cells, IgG1 secreting B cells, CTL, and IL-10 (+++)/IFN- γ (+) secreting CD4 T cells. In TH1 immune response, the effector cells are macrophages, IgG3 secreting B cells, CTL, and IFN- γ (+++)
 secreting CD4 T cells. Similarly different types of host immune response use different STAT proteins to initiate specific immune reactions. IL-4 activates STAT6 in TH2 immune response. TGF- β and IL-6 activates STAT3 β in TH17 immune response. Interferon alpha/beta and IL-10 activates STAT1 and STAT3 α in TH α β immune response. IL-12 activates STAT4 in TH1 immune response [12]. TGF- β and IL-2 activate STAT5 in regulatory T cell (Treg) immune response. Based on these data, malaria infection appears to induce a mixed TH17 and TH α β immune response which best fits with a model in which both pathways are activated during the onset and recovery from malaria infection.

Others have shown that TGF- β with IL-6 can induce TH17 immune response [10,11]. TH17 lymphocytes also produce large amounts of IL-8, TNF- α and IL-1, which recruit and activate neutrophils. Due to previous analysis, toll-like receptor 1, 2, 4, 7, 8 are up-regulated after malarial infection. TLR1/2/4 mainly induce anti-extracellular bacteria TH17 immune response. TLR7/8 binding to single strand RNA mainly induce anti-virus TH α β immune response. In addition, this study found a lot of heat shock proteins are up-regulated after malarial infection. Heat shock proteins, mainly HSP60 or HSP70, can activate TLR2/4 for inducing TH17 immune response. In this study, TGF- β , IL-1, and IL-8 were strongly up-regulated in acute malaria (Table 3). Although IL-17 was not up-regulated, the IL-6-related cytokine family gene oncostatin M, was up-regulated in acute malaria infection. oncostatin M can up-regulate STAT3 β , a key mediator in





Figure 6 Proposed model for the four types of host immune response. Green means unchanged and red means up-regulated genes after malaria infection. TH2 immune response is induced by STAT6 activated by IL-4. TH $\alpha\beta$ immune response is induced by STAT1 & STAT3 α activated by IFN- $\alpha\beta$. TH1 immune response is induced by STAT4 activated by IL-12. TH17 immune response is induced by STAT3 β activated by TGF- β /IL-6 to induce downstream PMN related genes and pro-inflammatory cytokines (TNF α , IL1, IL8). In TH $\alpha\beta$ immune response, IFN- $\alpha\beta$ can suppress STAT6. IFN- $\alpha\beta$ also suppress iNOS and IL-12 via IL-10 dependent mechanism. Up-regulated STAT1 can suppress GATA3 and STAT4. STAT1 can up-regulate IRF1, T-bet, IgG Fc receptors, Fas, C3a receptor. IRF1 induced TRAIL, T-bet induced NK cell killer receptors, and Fas can enhance NK cell cytotoxicity. Up-regulated IgG Fc receptors can mediate ADCC. In T cell, T-bet can up-regulate IFN- γ . Up-regulated IFN- γ can activate STAT1 signaling via IFN- γ receptor. However, the IFN- γ receptor is suppressed during lymphocyte maturation. Thus, TH $\alpha\beta$ immune response can be separated from TH1 immune response.

play central roles in the developmental process [2]. Although administration of IL-12 can provide 100% protection against malaria parasite challenge, IL-12 plays a limited role in natural immune response against malaria in mice [1]. Active immunosuppression is well documented during malaria infection in mice [3]. IL-12 expression is down-regulated in this model [23]. According to an IRF1 knock-out study, mice can initiate TH1 immune response by bypassing the need for IL-12 production through the use of an alternate interferon alpha/beta driven pathway [24]. Based on recent microarray studies in malaria-infected mice, there is no evidence of IL-12 up-regulation following infection. Instead, interferon alpha/beta and its related genes were found to be significantly up-regulated [25,26], thus providing further evidence at the gene level that interferon alpha/beta can substitute for IL-12 in the induction of malaria-specific interferon gamma TH1 type immune response after infection in rodents. However, the IFN $\alpha\beta$ driven TH $\alpha\beta$ immune response only can produce mid-to-moderate IFN γ , and IL-10, the main effector molecule in TH $\alpha\beta$ immune response, antagonizes the effect of IFN γ upon macrophages. Because the ideal traditional TH1 immune response cannot be triggered in natural malarial infection in human to clear out the protozoa, malaria parasites can cause severe illness in human.

In human, there is also a substantial amount of evidence indicating that TH1 immune response can be


induced by two pathways driven by $\alpha\beta$ interferon or IL-12 [27,28]. Administration of IL-12 to human subjects suppresses NK cell proliferation [29]. Macrophage activation serves to inhibit NK cell function, while NK cell activation serves to inhibit macrophage proliferation [19,30]. Given these observations, it is reasonable to speculate that these two effector cells belong to different immunological pathways. In the present study, this study found that a number of genes involved in the NK cell proliferation were up-regulated over the course of the malaria disease cycle (Table 1). In addition, as in the mouse model, genes associated with macrophage proliferation were not up-regulated following infection with *P. falciparum*. Increased NK cell populations have also been reported previously in acute malaria infection [31,32], thus, it appears that the interferon alpha/beta-NK cell pathway of TH $\alpha\beta$ immune response is preferentially enhanced after *P. falciparum* infection, while the IL-12 driven pathway appears unaffected. Other TH $\alpha\beta$ -related cytokines also can cause NK cell activation or proliferation including IL-10 and IL-15, respectively [33].

In human malarial infection, it has been shown that serum IL-12 levels are inversely correlated with malaria parasitaemia [6]. The more severe the malaria is, the lower IL-12 expression levels become. The uptake of malarial pigment (haemozoin) can down-regulate IL-12 secretion in human monocytes [5]. Malarial PGE2-like molecules can



also down-regulate IL-12 secretion [34]. Up-regulation of CD36 by malarial infection can inhibit dendritic cell maturation with decreasing IL-12/IL-10 ratio [4]. Although haemozoin, in certain studies, can activate TLR9, which is for traditional TH1 immune response, TLR9 was not detected in this study. In previous microarray analysis of human malarial infection, interferon inducible genes were up-regulated with unchanged IL-12 expression [14,35]. Other important components of TH $\alpha\beta$ immune response included up-regulation of HMOX1, FAS, BCL6, TNFRSF10A, and MIP1 α were noted in Griffiths' research [14], which studied the peripheral blood leukocytes from Kenyan


children with acute falciparum malaria. In this microarray study, this study found up-regulation of interferon alpha/beta, interferon gamma, NK cell activating receptors, Fas, TRAIL, Fc gamma receptors, ADCC-related genes, IL-15, granzymes, and TH1 related chemokines (IP10, CXCL9, CXCL11, CCL3, CCL4, CCR1). These observations are, in general, consistent with the development of TH $\alpha\beta$ immune response characterized by NK cell activation induced by alpha/beta interferon following *P. falciparum* infection. Genes associated with TH1 immune response driven by IL-12 and macrophage activation (iNOS up-regulation) were unchanged after malarial infection. Gene coding for a



number of macrophage de-activation molecules were up-regulated, including TGFβ receptor, CD36, CD163-Haem oxygenase1, and CD47-SIRPα. These molecules can actively suppress macrophage activation. When given alone and prior to malaria infection, IL-12 can provide 100% protection against experimental *Plasmodium* infection through the activation of macrophages, which help to control the liver stage of infection [1]. However, based on the data collected during the course of the current study, it also appears that infected individuals defend malaria through an alternate THαβ immune response, involving alpha/beta interferon and the activation of NK cells [36]. Interferon

gamma plays a central role in immune response against malaria. However, the natural host immune response is suboptimal because IFN-γ is not the main effector in THαβ immune response. The major effector cells of THαβ immune response are NK cells, and the major effector cells of traditional TH1 immune response are macrophages.

Although IL-10, a strong macrophage de-activator, was not up-regulated in this study, many downstream genes of IL-10 were up-regulated including haem oxygenase 1, and it suggests that IL-10 is actually up-regulated after malaria infection. In an ideal situation, TH1 immune response is basically immune response against intracellular



bacteria/protozoa; TH $\alpha\beta$ immune response is basically immune response against viruses. Although, it appears that macrophages may not be activated in natural immune response against malaria, interferon gamma(+) and IL-10(+++) secreting CD4 T cells, cytotoxic CD8 T cells, IgG secreting B cells, and NK cells are up-regulated by interferon alpha/beta in malarial infection. In a clinical study in Gabon, interferon- γ and IL-10 secreting CD4 T cells were increasing and correspondent to the recovery of *P. falciparum* infection [37]. Pure TH1 interferon- γ producing T cells and pure TH2 IL-4 producing T cells were not changed during convalescence

after malaria infection. Thus observation is consistent with a model in which interferon- γ and IL-10 secreting T cells play important roles in host immune response against malaria.

Conclusions

It appears that the human immune response to *P. falciparum* is characterized by a suboptimal TH α/β and TH17 bias, which predominates over the more ideal and effective traditional TH1 responses driven by IL-12. Since treatment for malarial infection faces some difficulty, such as drug resistance, this study strongly encourage

the use of IFN γ (FDA approval drug) or IL-12 for malarial infection treatment to achieve the optimal host immune response to kill the intracellular protozoa.

Competing interests

The author has declared that he has no competing interests.

Author's contributions

W-CH, is responsible for the conception and design of this study, for data acquirement and analysis, for manuscript preparation, and for final approval and submission.

Acknowledgements

I am thankful for Dr Roger Moyou for his help of accessing patients in Cameroon. I also thank M Nau, A Arnold and A Jedlicka for expert technical assistance. I really appreciate Professor P C Huang, Professor August Louis Bourgeois and Professor Alan Scott for their assistance in writing this manuscript.

Received: 18 July 2013 Accepted: 22 October 2013

Published: 5 November 2013

References

1. Sedegah M, Finkelman F, Hoffman SL: **Interleukin 12 induction of interferon gamma-dependent protection against malaria.** *Proc Natl Acad Sci U S A* 1994, **91**:10700–10702.
2. Su Z, Stevenson MM: **Central role of endogenous gamma interferon in protective immunity against blood-stage Plasmodium chabaudi AS infection.** *Infect Immun* 2000, **68**:4399–4406.
3. Ocana-Morgner C, Mota MM, Rodriguez A: **Malaria blood stage suppression of liver stage immunity by dendritic cells.** *J Exp Med* 2003, **197**:143–151.
4. Urban BC, Ferguson DJ, Pain A, Willcox N, Plebanski M, Austyn JM, Roberts DJ: **Plasmodium falciparum-infected erythrocytes modulate the maturation of dendritic cells.** *Nature* 1999, **400**:73–77.
5. Keller CC, Yamo O, Ouma C, Ong'echa JM, Ounah D, Hittner JB, Vulule JM, Perkins DJ: **Acquisition of hemozoin by monocytes down-regulates interleukin-12 p40 (IL-12p40) transcripts and circulating IL-12p70 through an IL-10-dependent mechanism: in vivo and in vitro findings in severe malarial anemia.** *Infect Immun* 2006, **74**:5249–5260.
6. Boutlis CS, Lagog M, Chaisavaneeyakorn S, Misukonis MA, Bockarie MJ, Mgone CS, Wang Z, Morahan G, Weinberg JB, Udhayakumar V, Anstey NM: **Plasma interleukin-12 in malaria-tolerant papua new guineans: inverse correlation with Plasmodium falciparum parasitemia and peripheral blood mononuclear cell nitric oxide synthase activity.** *Infect Immun* 2003, **71**:6354–6357.
7. Ockenhouse CF, Hu WC, Kester KE, Cummings JF, Stewart A, Heppner DG, Jedlicka AE, Scott AL, Wolfe ND, Vahey M, Burke DS: **Common and divergent immune response signaling pathways discovered in peripheral blood mononuclear cell gene expression patterns in presymptomatic and clinically apparent malaria.** *Infect Immun* 2006, **74**:5561–5573.
8. Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, Wang Y, Hood L, Zhu Z, Tian Q, Dong C: **A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17.** *Nat Immunol* 2005, **6**:1133–1141.
9. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL: **Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins.** *J Immunol* 1986, **136**:2348–2357.
10. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, Weaver CT: **Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages.** *Nat Immunol* 2005, **6**:1123–1132.
11. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK: **Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells.** *Nature* 2006, **441**:235–238.
12. Yu CR, Lin JX, Fink DW, Akira S, Bloom ET, Yamauchi A: **Differential utilization of Janus kinase-signal transducer activator of transcription signaling pathways in the stimulation of human natural killer cells by IL-2, IL-12, and IFN-alpha.** *J Immunol* 1996, **157**:126–137.
13. Zhang F, Li C, Halfter H, Liu J: **Delineating an oncostatin M-activated STAT3 signaling pathway that coordinates the expression of genes involved in cell cycle regulation and extracellular matrix deposition of MCF-7 cells.** *Oncogene* 2003, **22**:894–905.
14. Griffiths MJ, Shafi MJ, Popper SJ, Hemingway CA, Kortok MM, Wathen A, Rockett KA, Mott R, Levin M, Newton CR, et al: **Genomewide analysis of the host response to malaria in Kenyan children.** *J Infect Dis* 2005, **191**:1599–1611.
15. Ladhani S, Lowe B, Cole AO, Kowuondo K, Newton CR: **Changes in white blood cells and platelets in children with falciparum malaria: relationship to disease outcome.** *Br J Haematol* 2002, **119**:839–847.
16. Senaldi G, Vesin C, Chang R, Grau GE, Piguet PF: **Role of polymorphonuclear neutrophil leukocytes and their integrin CD11a (LFA-1) in the pathogenesis of severe murine malaria.** *Infect Immun* 1994, **62**:1144–1149.
17. Pittet JF, Griffiths MJ, Geiser T, Kaminski N, Dalton SL, Huang X, Brown LA, Gotwals PJ, Koteliansky VE, Matthay MA, Sheppard D: **TGF-beta is a critical mediator of acute lung injury.** *J Clin Invest* 2001, **107**:1537–1544.
18. Schrier RW, Wang W, Poole B, Mitra A: **Acute renal failure: definitions, diagnosis, pathogenesis, and therapy.** *J Clin Invest* 2004, **114**:5–14.
19. Bordignon C, Villa F, Allavena P, Introna M, Biondi A, Avallone R, Mantovani A: **Inhibition of natural killer activity by human bronchoalveolar macrophages.** *J Immunol* 1982, **129**:587–591.
20. Jackson JD, Yan Y, Brunda MJ, Kelsey LS, Talmadge JE: **Interleukin-12 enhances peripheral hematopoiesis in vivo.** *Blood* 1995, **85**:2371–2376.
21. Orange JS, Biron CA: **Characterization of early IL-12, IFN-alpha, and TNF effects on antiviral state and NK cell responses during murine cytomegalovirus infection.** *J Immunol* 1996, **156**:4746–4756.
22. Wang X, Chen M, Wandinger KP, Williams G, Dhib-Jalbut S: **IFN-beta-1b inhibits IL-12 production in peripheral blood mononuclear cells in an IL-10-dependent mechanism: relevance to IFN-beta-1b therapeutic effects in multiple sclerosis.** *J Immunol* 2000, **165**:548–557.
23. Xu X, Sumita K, Feng C, Xiong X, Shen H, Maruyama S, Kanoh M, Asano Y: **Down-regulation of IL-12 p40 gene in Plasmodium berghoi-infected mice.** *J Immunol* 2001, **167**:235–241.
24. Feng C, Watanabe S, Maruyama S, Suzuki G, Sato M, Furuta T, Kojima S, Taki S, Asano Y: **An alternate pathway for type 1 T cell differentiation.** *Int Immunol* 1999, **11**:1185–1194.
25. Sexton AC, Good RT, Hansen DS, D'Ombrian MC, Buckingham L, Simpson K, Schofield L: **Transcriptional profiling reveals suppressed erythropoiesis, up-regulated glycolysis, and interferon-associated responses in murine malaria.** *J Infect Dis* 2004, **189**:1245–1256.
26. Schaefer K, Kumar S, Yadava A, Vahey M, Ockenhouse CF: **Genome-wide expression profiling in malaria infection reveals transcriptional changes associated with lethal and nonlethal outcomes.** *Infect Immun* 2005, **73**:6091–6100.
27. Brinkmann V, Geiger T, Alkan S, Heusser CH: **Interferon alpha increases the frequency of interferon gamma-producing human CD4+ T cells.** *J Exp Med* 1993, **178**:1655–1663.
28. Cousens LP, Peterson R, Hsu S, Dorner A, Altman JD, Ahmed R, Biron CA: **Two roads diverged: interferon alpha/beta- and interleukin 12-mediated pathways in promoting T cell interferon gamma responses during viral infection.** *J Exp Med* 1999, **189**:1315–1328.
29. Kohl S, Sigaroudinia M, Charlebois ED, Jacobson MA: **Interleukin-12 administered in vivo decreases human NK cell cytotoxicity and antibody-dependent cellular cytotoxicity to human immunodeficiency virus-infected cells.** *J Infect Dis* 1996, **174**:1105–1108.
30. Spitzer G, Verma DS: **Cells with Fc gamma receptors from normal donors suppress granulocytic macrophage colony formation.** *Blood* 1982, **60**:758–766.
31. Wyler DJ: **Peripheral lymphocyte subpopulations in human falciparum malaria.** *Clin Exp Immunol* 1976, **23**:471–476.
32. Kassa D, Petros B, Mesele T, Hailu E, Wolday D: **Characterization of peripheral blood lymphocyte subsets in patients with acute Plasmodium falciparum and P. vivax malaria infections at Wonji Sugar Estate, Ethiopia.** *Clin Vaccine Immunol* 2006, **13**:376–379.
33. Robertson MJ, Soiffer RJ, Wolf SF, Manley TJ, Donahue C, Young D, Herrmann SH, Ritz J: **Response of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of NK cells are differentially regulated by NKSF.** *J Exp Med* 1992, **175**:779–788.
34. Kilunga Kubata B, Eguchi N, Urade Y, Yamashita K, Mitamura T, Tai K, Hayaishi O, Horii T: **Plasmodium falciparum produces prostaglandins that**

are pyrogenic, somnogenic, and immunosuppressive substances in humans. *J Exp Med* 1998, **188**:1197–1202.

35. Daily JP, Le Roch KG, Sarr O, Fang X, Zhou Y, Ndir O, Mboup S, Sultan A, Winzeler EA, Wirth DF: **In vivo transcriptional profiling of *Plasmodium falciparum***. *Malar J* 2004, **3**:30.
36. Herberman RR, Ortaldo JR, Bonnard GD: **Augmentation by interferon of human natural and antibody-dependent cell-mediated cytotoxicity**. *Nature* 1979, **277**:221–223.
37. Winkler S, Willheim M, Baier K, Schmid D, Aichelburg A, Graninger W, Kremsner PG: **Reciprocal regulation of Th1- and Th2-cytokine-producing T cells during clearance of parasitemia in *Plasmodium falciparum* malaria**. *Infect Immun* 1998, **66**:6040–6044.

doi:10.1186/1475-2875-12-392

Cite this article as: Hu: Human immune responses to *Plasmodium falciparum* infection: molecular evidence for a suboptimal TH α β and TH17 bias over ideal and effective traditional TH1 immune response. *Malaria Journal* 2013 **12**:392.

**Submit your next manuscript to BioMed Central
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

